Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Oct 1;14(19):5967-76.
doi: 10.1158/1078-0432.CCR-07-4535.

Validation of analytic methods for biomarkers used in drug development

Affiliations
Review

Validation of analytic methods for biomarkers used in drug development

Cindy H Chau et al. Clin Cancer Res. .

Abstract

The role of biomarkers in drug discovery and development has gained precedence over the years. As biomarkers become integrated into drug development and clinical trials, quality assurance and, in particular, assay validation become essential with the need to establish standardized guidelines for analytic methods used in biomarker measurements. New biomarkers can revolutionize both the development and use of therapeutics but are contingent on the establishment of a concrete validation process that addresses technology integration and method validation as well as regulatory pathways for efficient biomarker development. This perspective focuses on the general principles of the biomarker validation process with an emphasis on assay validation and the collaborative efforts undertaken by various sectors to promote the standardization of this procedure for efficient biomarker development.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Integration of the biomarker assay validation and the qualification process with drug development (see text for a description of each process).

Similar articles

Cited by

References

    1. Park JW, Kerbel RS, Kelloff GJ, et al. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res. 2004;10:3885–96. - PubMed
    1. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006;24:971–83. - PubMed
    1. Medicine Zerhouni E. The NIH Roadmap. Science. 2003;302:63–72. - PubMed
    1. Owzar K, Barry WT, Jung S-H, Sohn I, George SL. Statistical challenges in preprocessing in microarray experiments in cancer. Clin Cancer Res. 2008;18 in press. - PMC - PubMed
    1. Taylor JMG, Ankerst DP, Andridge RR. Validation of biomarker-based risk prediction models. Clin Cancer Res. 2008;18 in press. - PMC - PubMed